• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell . Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

tetano

Editor, Senior Moderator
Cell


. 2020 Aug 5;S0092-8674(20)30993-4.
doi: 10.1016/j.cell.2020.08.002. Online ahead of print.
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19


Aymeric Silvin[SUP] 1 [/SUP], Nicolas Chapuis[SUP] 2 [/SUP], Garett Dunsmore[SUP] 1 [/SUP], Anne-Ga?lle Goubet[SUP] 1 [/SUP], Agathe Dubuisson[SUP] 1 [/SUP], Lisa Derosa[SUP] 3 [/SUP], Carole Almire[SUP] 4 [/SUP], Cl?mence H?non[SUP] 5 [/SUP], Olivier Kosmider[SUP] 2 [/SUP], Nathalie Droin[SUP] 6 [/SUP], Philippe Rameau[SUP] 7 [/SUP], Cyril Catelain[SUP] 7 [/SUP], Alexia Alfaro[SUP] 7 [/SUP], Charles Dussiau[SUP] 2 [/SUP], Chlo? Friedrich[SUP] 2 [/SUP], Elise Sourdeau[SUP] 8 [/SUP], Nathalie Marin[SUP] 9 [/SUP], Tali-Anne Szwebel[SUP] 10 [/SUP], Delphine Cantin[SUP] 8 [/SUP], Luc Mouthon[SUP] 11 [/SUP], Didier Borderie[SUP] 12 [/SUP], Marc Deloger[SUP] 7 [/SUP], Delphine Bredel[SUP] 1 [/SUP], Severine Mouraud[SUP] 1 [/SUP], Damien Drubay[SUP] 13 [/SUP], Muriel Andrieu[SUP] 14 [/SUP], Anne-Sophie Lhonneur[SUP] 15 [/SUP], V?ronique Saada[SUP] 16 [/SUP], Annabelle Stoclin[SUP] 17 [/SUP], Christophe Willekens[SUP] 18 [/SUP], Fanny Pommeret[SUP] 19 [/SUP], Frank Griscelli[SUP] 20 [/SUP], Lai Guan Ng[SUP] 21 [/SUP], Zheng Zhang[SUP] 22 [/SUP], Pierre Bost[SUP] 23 [/SUP], Ido Amit[SUP] 24 [/SUP], Fabrice Barlesi[SUP] 19 [/SUP], Aur?lien Marabelle[SUP] 25 [/SUP], Fr?d?ric P?ne[SUP] 26 [/SUP], Bertrand Gachot[SUP] 17 [/SUP], Fabrice Andr?[SUP] 27 [/SUP], Laurence Zitvogel[SUP] 28 [/SUP], Florent Ginhoux[SUP] 29 [/SUP], Michaela Fontenay[SUP] 30 [/SUP], Eric Solary[SUP] 31 [/SUP]



Affiliations

Abstract

Blood myeloid cells are known to be dysregulated in coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2. It is unknown whether the innate myeloid response differs with disease severity and whether markers of innate immunity discriminate high-risk patients. Thus, we performed high-dimensional flow cytometry and single-cell RNA sequencing of COVID-19 patient peripheral blood cells and detected disappearance of non-classical CD14[SUP]Low[/SUP]CD16[SUP]High[/SUP] monocytes, accumulation of HLA-DR[SUP]Low[/SUP] classical monocytes (Human Leukocyte Antigen - DR isotype), and release of massive amounts of calprotectin (S100A8/S100A9) in severe cases. Immature CD10[SUP]Low[/SUP]CD101[SUP]-[/SUP]CXCR4[SUP]+/-[/SUP] neutrophils with an immunosuppressive profile accumulated in the blood and lungs, suggesting emergency myelopoiesis. Finally, we show that calprotectin plasma level and a routine flow cytometry assay detecting decreased frequencies of non-classical monocytes could discriminate patients who develop a severe form of COVID-19, suggesting a predictive value that deserves prospective evaluation.

Keywords: COVID-19; S100A8; S100A9; SARS-CoV-2; calprotectin; emergency myelopoiesis; monocyte subsets; neutrophils; type I interferon.
 
Back
Top Bottom